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Available online 4 August 2016This case series describes the use of pelvic radiotherapy (RT) and MRI-based intracavitary brachytherapy (ICBT)
for patients with small volume, early-stage, primary vaginal cancer.
A customized pelvic MRI protocol with a vaginal cylinder in place (MRVC) was used to measure disease extent
and tumor thickness (deﬁned as distance from lateral/apical margin of tumor to cylinder surface) at time of di-
agnosis. Non-bulky tumors with initial (pre-RT) thickness ≤ 2 cm from the cylinder surface received pelvic RT
followed by ICBT.
Ten patients with FIGO stage I–II primary vaginal cancer treatedwith pelvic RT+/− cisplatin and ICBT at our in-
stitution between 1998 and 2008 were included. Initial tumor thickness measured on MRVC ranged from 0 to
2 cm. Initial tumor volume ranged from 0 to 9.8 cm3. Mean pelvic RT dose was 45 Gy. At the time of ICBT, 60%
of patients had a complete response (cR) and 40% had a partial response (pR). No patients with a cR had a recur-
rence whereas one patient with a pR had a local recurrence following ICBT. For the entire cohort, themedian fol-
low-up time was 59.9 months (range: 15–153). The estimated 5-year overall survival, disease-speciﬁc survival,
and local failure-free survival were 67%, 80%, and 90%, respectively. Among survivors, there were no late grade
3–4 toxicities.
In this series of patientswith small primary early-stage vaginal tumors, long term clinical outcomeswere accept-
able following RT and MRI-based ICBT, especially among those with a cR at time of brachytherapy.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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MRI1. Introduction
Vaginal cancer is rare, comprising approximately 1–3% of all gyneco-
logic cancers. The American Cancer Society estimates that in 2015 ap-
proximately 4070 new cases of vaginal cancer will be diagnosed, and
910 women will die from this disease (http://www.cancer.org/cancer/
vaginalcancer/detailedguide/vaginal-cancer-key-statistics). Multiple
single-institution studies have shown that excellent disease-speciﬁc
survival and pelvic disease control can be obtained in patients with
early-stage disease (Frank et al., 2005; Perez et al., 1999; Chyle et al.,
1996). Brachytherapy is an integral component of treatment and must
be carefully tailored to the size and extent of the tumor (Beriwal et al.,
2012a; Lee et al., 2013).
The type of brachytherapy used in vaginal cancer is highly individu-
alized, and decisions about brachytherapy boostmodality may be based
on size, location, and thickness of vaginal tumor as detailed on a pelvic
MRI (Elsayes et al., 2007; Taylor et al., 2007; Gardner et al., 2015).tic Radiology, Smilow Cancer
040, USA.
. This is an open access article underHowever, due to the extreme rarity of vaginal cancer, studies analyzing
howMRI information guides brachytherapy technique in vaginal cancer
have been scarce (Dimopoulos et al., 2012; Vargo et al., 2015; Beriwal et
al., 2012b).
At our in ≤ stitution, in the late 1990s, we developed anMRI protocol
with a vaginal cylinder in place (MRVC) for the assessment of pelvic tu-
mors. The information provided by the MRVC was used to document
initial tumor extent and thickness and to select the appropriate brachy-
therapy boost modality. Patients with small primary vaginal tumors
with an initial thickness ≤ 2 cm were considered for external beam ra-
diotherapy (EBRT) followed by intra-cavitary brachytherapy (ICBT).
The present case series seeks to describe the long-term outcomes of pa-
tients with early stage vaginal cancer who were treated deﬁnitively at
our institution with EBRT and ICBT, using MRVC.
2. Material and methods
2.1. Patient population
This study was approved by the Institutional Human Investigations
Committee. We performed a retrospective review of patients withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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py (RT) with curative intent in our department over a 10-year period
(1998–2008). Patients with a previous history of invasive carcinoma
of the female genital tract and those treated with palliative intent
were excluded. Initial search results yielded 16 patients with stage I-II
primary vaginal carcinoma. Additional exclusions were: bulky early
stage cases treated with interstitial or EBRT boost (n = 2), early stage
ICBT cases which lacked pre-treatment MRI imaging (n = 3), and one
patient from an outside institutionwith no follow-up records accessible
(n = 1).
The ﬁnal study population of 10 patients received MRI-based ICBT
following EBRT. Pre-treatment evaluation included an examination
under anesthesia for documentation of disease extent in clinical dia-
grams, a CT scan of the chest, abdomen, and pelvis, and an MRI of the
pelvis with the MRVC protocol, as described below.
2.2. MRI imaging protocol
All patients underwent customized pelvic MRI imaging with a vagi-
nal cylinder (MRVC) prior to RT. Prior to the date of imaging, patients
were ﬁtted with the appropriate size vaginal cylinder in the clinic. The
single-channel cylinders utilized at our institution are made of Lucite,
and fabricated in our department. Cylinders measure 14 cm in length
and are available in diameters of 2.0, 2.3, 2.6 or 3.0 cm. At the time of im-
aging, the radiation oncologist placed the appropriate sized Lucite cylin-
der into the vaginal canal. MRI was performed on a 1.5 T magnet
(General Electric Medical Systems,Milwaukee,WI, USA) using a phased
array coil with the axial sequences performed perpendicular to the long
axis of the cylinder and the sagittal and coronal planes performed paral-
lel to the cylinder's long axis. A FOV (ﬁeld of view) typically of 24 cm,
and a 256 × 256matrix centered on the tip of the cylinder was utilized;
T2 and T1 weighted scans, 4 mm thick (skip 4.8 mm), were obtained.
Subtracted volumetric 1mmpre and post iv contrast enhanced, fat sup-
pressed gradient echo with gadodiamide (Omiscan; Amersham,
Princeton, NJ, 20 ml) were acquired in the axial plane. Larger FOV sagit-
tal 3D T2 and fat saturated T2weighted scans of the pelvis were obtain-
ed as well as a post enhanced scan of the pelvis to include the aortic
bifurcation and inguinal regions to assess for any adenopathy.
2.3. External beam radiotherapy
All patients received pelvic EBRT with a prescribed dose of 4500–
4600 cGy in 23–25 fractions. For tumors involving the upper vagina,
the targets included the entire vagina/paravaginal region, pelvic side-
walls and the bilateral pelvic lymph nodes with a 4-ﬁeld box technique.
The inguinal lymph nodes were also treated in cases where there was
involvement of the lower third of the vagina. Concomitant cisplatin che-
motherapy (40mg/m2)was considered for patientswith stage II disease
during this time period.
2.4. Intra-cavitary brachytherapy
All patients received either high-dose-rate (HDR) or low-dose-rate
(LDR) ICBT, depending on the year of treatment. For those treated
with HDR, treatments were delivered on an outpatient weekly basis,
with an Iridium-192 afterloader. The total doses of brachytherapy
ranged from 18 to 21 Gy, in 3–5 fractions, prescribed to 5-10 mm
depth, depending on disease extent. The same size single lumen vaginal
cylinder utilized for the MRVC was also used for treatment. Treatment
plans were customized for each patient, specifying the prescription
depth as well as the length of vagina to be treated, based on the location
and extent of disease evident on physical examination and imaging, and
marked out on the cylinders. Dosewas optimized on a phantom, and 3D
planning was not utilized. In general, the entire vagina was treated to a
minimumEQD2 dose of approximately 60Gywith additional dose given
to boost the tumor bed and areas of higher risk to approximately 75 Gy.In select cases, partially shielded cylinders were used for one or more
brachytherapy fractions in order to reduce the dose to uninvolved re-
gions of the vagina and the adjacent critical structures.
2.5. Patient follow-up and outcomes assessment
All patients had clinical examination every 2–3 months for the ﬁrst
2 years, and every 3–4 months until 5 years, and then at least every
6–12months thereafter. Vaginal cytologywas obtained every 3months.
For patients with an incomplete or uncertain response, serial MRVC
studies were performed to document radiographic regression.
Follow-up timewas calculated from the date of diagnosis to the date
of the last gynecologic examination. Actuarial rates of local recurrence,
disease-speciﬁc, and overall survival were estimated by the Kaplan-
Meier method. Toxicity was recorded in clinic notes and retrospectively
graded according to the Common Terminology Criteria for Adverse
Events (CTCAE v4.0).
3. Results
A total of 10 patients with early stage primary vaginal cancer were
included with characteristics shown in Table 1. Four patients were
FIGO stage I and six patients were FIGO stage II. All patients were
node-negative. Themean age was 69.6 years (range: 54–88). Histologic
subtypes included: squamous cell carcinoma (n = 6), adenocarcinoma
(n = 3), and neuroendocrine carcinoma (n = 1). Tumor location was
distal (n=4),mid (n=1), or upper (n=5). Following EBRT, seven pa-
tients received HDR ICBT and three received LDR ICBT. Cumulative
equivalent dose delivered to tumor (EBRT + ICBT) for each patient is
shown in Table 1. On average, higher doses (EQD2) were prescribed
for apical tumors (~75–80 Gy) as compared to tumors in mid- or distal
vaginal locations (~70–75 Gy).
In terms of imaging assessment of tumor extent, as shown in Table 2,
themean initial ellipsoid tumor volume in cubic centimeters (volume=
height × width × thickness × pi / 6) (Mayr et al., 2002) was 3.3 cm
cubed (range: 1.3–9.8 cm3). Initial tumor thickness prior to EBRT as
measured on the customized MRVC ranged from 0 to 20 mm from the
cylinder surface, with a mean pre-EBRT thickness of 13 mm. At the
time of ICBT, 60% of patients had a clinical complete response (cR).
Four patients (40%) had a partial or uncertain response (pR). All patients
achieved an eventual cR documented in subsequent followup visits. Fig.
1A–F illustrates serialMRVC imaging performed every fewmonths until
complete regression for one patient with a pR at time of ICBT (patient
#7, Tables 1–2).
The median followup time was 59.9 months (range: 15–153). The
estimated 5-year overall survival, disease-speciﬁc survival, and local
failure-free survival were 67%, 80%, and 90%, respectively. There was
one local recurrence and one distant failure. The local recurrence oc-
curred in a patientwith stage II SCC of the distal vagina/peri-urethral re-
gion. Her initial tumor thickness was 15 mm as documented on MRVC
prior to EBRT. She had only a pR at time of ICBT, with residual thickness
of 5mmonMRVC at time of ICBT. She had a cR at 6weekswith negative
cytology. However, she developed a local recurrence 4 months post
ICBT. Following PET/CT imaging and histologic conﬁrmation, she re-
quired a pelvic exenteration.
As shown in Table 2, of the 8 patients with long-term followup who
remained disease-free, therewere no late grade 3–4 toxicities (Table 2).
4. Discussion
The patie ≤nts in this series had early stage primary vaginal cancer
(FIGO I–II) with non-bulky (mean tumor volume 3.3 cm3, range: 1.3–
9.8 cm3) vaginal tumors with initial thickness ≤ 2 cm, as measured
from the cylinder surface to the lateral/apical margin of the tumor on
MRVC prior to any treatment. MRVC provided valuable information
with respect to the dimensions of the tumor, which complimented the
Table 1
Treatment characteristics of early stage vaginal cancer patients (n = 10).
Subject
number
Age Pre-RT
excision
FIGO
stage
Histology Degree of
differentiation
Concurrent
cisplatin
EBRT dose
(cGy)
ICBT boost
modality
Tumor location Cumulative equivalent dose
(EQD2) to tumor at depth 5 mm
(Gy)
1 70 Yes,
partial
I NEC PD No 4500 HDR Distal third of vagina, posterior wall 69.3
2 77 No II SCC NS No 4500 HDR Mid right vaginal wall, 4 cm from
introitus, 2 cm from fornices
68.3
3 63 No II SCC NS Yes 4500 HDR Distal vaginal mass on anterior
vaginal wall abutting urethral
meatus
67.6
4 88 No I SCC WD No 3400 HDR Distal, just inside introitus on left
side
66.3
5 72 No II SCC MD No 4500 HDR Distal, just inside introitus on right
side
74
6 68 No I AC PD No 4500 HDR Apex 74
7 67 No I AC PD No 4500 HDR Apex, left superior 74
8 61 No II SCC PD Yes 4500, MLB
after 3060
LDR Apex, right lateral and anterior walls 80
9 54 Yes,
partial
II SCC MD Yes 4500, MLB
after 3060
LDR Apex 84
10 76 No II AC PD Yes 4500, MLB
after 3960
LDR Apex, right fornix extending to right
vaginal wall
87
Abbreviations: RT = radiotherapy; FIGO = International Federation of Gynecology and Obstetrics; NEC = neuroendocrine carcinoma; SCC = squamous cell carcinoma; AC =
adenocarcinoma; PD = poorly differentiated; NS = not speciﬁed; WD= well differentiated; MD=moderately differentiated; EBRT = external beam RT; MLB = midline block; ICBT
= intracavitary brachytherapy; HDR = high-dose-rate; LDR = low-dose-rate.
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plete response at timeof intra-cavitary brachytherapy.We found that long
term outcomes were acceptable, both in terms of tumor control and late
toxicities, and were comparable to prior single institution reports (Frank
et al., 2005; Perez et al., 1999; Chyle et al., 1996; Kucera et al., 2001).
This series is a unique contribution to the sparse literature on out-
comes of vaginal cancer patients treated in the era of MRI
(Dimopoulos et al., 2012; Vargo et al., 2015; Beriwal et al., 2012b).
Stage II lesions and lesions involving the distal vagina were boosted
with ICBT, whereas at other institutions these might be treated prefer-
entially with interstitial brachytherapy (Frank et al., 2005; Perez et al.,Table 2
Pre-EBRT measurements, tumor response, long-term outcomes and toxicity.
Subject
number
Initial tumor thickness
(distance from cylinder to
lateral margin of mass)
measured on pre-EBRT MRI
(mm)
Initial tumor dimension
(cm) as measured on
pre-EBRT MRI (AP × TV ×
CC)− volume in
parenthesis in cc
Initial Tumor size
(cm) as estimated
clinically by exam
(length × width)
1 0 0 (0) 1 × 1
2 10 2.0 × 2.0 × 1.0 (2.1) 2.5 × 2
3 15 1.5 × 1.3 × 3.7 (3.8) 2 × 1
4 13 2.3 × 1.2 × 0.9 (1.3) 1 × 2
5 8 1.2 × 2.4 × 1.8 (2.7) 2 × 2
6 10 2.0 × 2.7 × 2.1 (5.9) 1 × 1.5
7 10 2.4 × 1.8 × 1.0 (2.3) 1.5 × 1.5
8 12 1.2 × 0.6 × 5.3 (2.0) 5 × 1.5
9 20 1.1 × 2.1 × 2.4 (2.9) 2 × 1
10 12 2.8 × 2.3 × 2.9 (9.8) 2.5 × 1
Abbreviations: EBRT= external beam radiotherapy; AP= anterior-posterior; TV= transverse;
partial response; DoD = died of disease; NED = no evidence of disease; RB = rectal bleeding;1999). An ICBT approach was chosen for several reasons: First, MRVC
allowed for careful selection of thin, non-bulky stage I-II lesions, as de-
scribed above. Second, the use of shielded vaginal cylinders coupled
with a detailed assessment of tumor location and vaginal anatomy
allowed boosting of selected portions of the vaginal wall without
overtreating the uninvolved mucosa, a goal which is also achievable
with multi-channel vaginal cylinders (Vargo et al., 2015). There were
no late grade 3–4 toxicities observed among survivorswhowere treated
with this approach.
Unfortunately, one patient in our series with residual disease and
tumor thickness ~ 5 mm at time of ICBT did have a local recurrence.Clinical
response
at time
of ICBT
Local
recurrence
Distant
metastases
Survival
time
(mo)
Disease
status at
time of
last
follow-up
Late toxicity
CR No Yes – lung
metastases
34 DoD Grade 2 RB
CR No No 38 Alive,
NED
None
PR Yes – had
exenteration
No 15 DoD Fistula related to
exenteration
CR No No 59 Died, NED None
CR No No 122 Alive,
NED
Grade 1 chronic
pelvic pain
PR No No 153 Alive,
NED
Grade 2 RB; Grade 2
vaginal dryness
PR No No 109 Alive,
NED
Grade 1 chronic
pelvic pain; Grade 2
rectal urgency; Grade
1 VS
CR No No 104 Alive,
NED
None
CR No No 41 Alive,
NED
None
PR No No 61 Died, NED Grade 2 RB; Grade 2
radiation dermatitis;
Grade 2 urinary
incontinence; Grade
2 VS
CC= cranial-caudal; ICBT= intracavitary brachytherapy; CR= complete response; PR=
VS= vaginal stenosis.
Fig. 1.A–F: Use of anMRI protocol with vaginal cylinder in place (MRVC) to serially document disease regression in patient #7with T1N0 poorly differentiated primary vaginal carcinoma
in the left superior vaginal apex (A) at time of vaginal cancer diagnosis (B) 1 month after RT and ICBT completed (C) 3 months post completion of RT (D) 9 months post-completion (E)
18 months post completion and (F) 24 months post completion. Note different bony landmarks over time due to vaginal shortening due to radiation. At 24 months the scan was read as
negative. During this 24 month period, vaginal cytology and clinical exam were negative.
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sulted in a better outcome remains unknown. An MRI performed with
the brachytherapy applicator in situ for the purpose of treatment plan-
ning not only can add detail about tumor responsiveness and biology
but furthermore can allow for more targeted brachytherapy dose esca-
lation and sparing of normal tissues (Viswanathan et al., 2013). Encour-
aging results using an MRI-guided adaptive brachytherapy approach
with locally advanced primary vaginal cancer have been published
(Dimopoulos et al., 2012).
There are numerous limitations to our data. Data are retrospective
and reﬂect a single institutional experience. Although the brachythera-
py in this series wasMRI-based, it was not MRI-guided in the sense that
MRI was obtained prior to EBRT rather than at the time of ICBT for the
purpose of conceptual planning (Viswanathan et al., 2013). Nonethe-
less, there are principles illustrated about usefulness of MR imaging
and tumor responsiveness, which remain applicable in the image-guid-
ed adaptive brachytherapy era, as many patients with small primary
vaginal tumors are appropriate for ICBT.
From these data, we conclude that small tumors (tumor
volume b 10 cm3) and those with initial tumor thickness
measured ≤ 2 cm from the surface of the cylinder to the lateral/apical
margin of tumor on pre-RT MRVC may be appropriate candidates for
an ICBT boost. Patients with a complete response to EBRT had excellent
resultswith this approach. Utilization of image-guided adaptive brachy-
therapy with consideration of an interstitial boost is highly encouraged
for small vaginal tumors which achieve a partial response following
~40–45 Gy EBRT.Conﬂict of interest
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